This post was originally published on this site
The drugmaker also raised its annual profit forecast to $15.25 to $16.75 per share from $14.25 to $16.00 previously.
Samsung Biologics Co Ltd said in January it plans to acquire Biogen (NASDAQ:BIIB)’s entire stake in their Samsung Bioepis joint venture worth $2.33 billion.
Net income attributable to Biogen rose to $1.06 billion, or $7.24 per share, in the quarter ended June 30, from $448.5 million, or $2.99 per share, a year ago.
